Hematopoietic Stem Cell Transplantation Improves Outcomes in Pediatric Patients with High-Risk Acute Myeloid Leukemia

Strategic Insights -

A new study conducted by researchers at the University of California San Francisco (UCSF) has found that hematopoietic stem cell transplantation (HSCT) significantly improves outcomes in pediatric patients with high-risk acute myeloid leukemia (AML). The study, published in the Journal of Clinical Oncology, analyzed data from two phase III clinical trials, AAML0531 and AAML1031, which established the prognostic importance of measurable residual disease (MRD) and high-risk cryptic cytogenetic/molecular (CM) alterations.

Key Takeaways:

  • The study included 463 patients with high-risk CM alterations and 72 patients with standard-risk (SR) CM results with positive MRD at end of induction I.
  • 33.9% and 45.8% of these groups underwent HSCT in CR1, respectively.
  • HSCT was associated with decreased relapse and improved disease-free survival (DFS) in both groups.
  • In the high-risk CM group, 5-year DFS was 26.0% (95% CI, 20.6 to 31.6) for HSCT, compared to 49.8% (95% CI, 41.7 to 57.4) for chemotherapy alone (P = 0.004).
  • The researchers concluded that HSCT was associated with improved outcomes in pediatric patients with contemporarily defined high-risk AML.

Statistics:

  • 463 patients with high-risk CM alterations were included in the study.
  • 72 patients with standard-risk (SR) CM results with positive MRD at end of induction I were included in the study.
  • 33.9% of high-risk CM patients underwent HSCT in CR1.
  • 45.8% of low-risk CM patients underwent HSCT in CR1.
  • 5-year DFS was 26.0% (95% CI, 20.6 to 31.6) for HSCT in high-risk CM patients.
  • 5-year DFS was 49.8% (95% CI, 41.7 to 57.4) for chemotherapy alone in high-risk CM patients.

Sources:

  • NewsRx. Findings from University of California San Francisco (UCSF) Provide New Insights into Cell Transplants (Hematopoietic Stem Cell Transplantation Outcomes for High-risk Aml: a Report From the Children's Oncology Group). Pediatrics Week. July 12, 2025; p 432.
  • Huang BJ, Wang W, Meyer LK, et al. Hematopoietic Stem Cell Transplantation Outcomes for High-risk Aml: a Report From the Children's Oncology Group. Journal of Clinical Oncology, 2025;43(17).
  • Children's Oncology Group, NIH National Cancer Institute (NCI), St Baldrick's Foundation Consortium Grant.